H Akaza

Summary

Affiliation: University of Tsukuba
Country: Japan

Publications

  1. ncbi A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 2 1 1 Amakubo, Tsukuba 305 0005, Japan
    Int J Clin Oncol 11:434-40. 2006
  2. doi Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    Oncology 78:323-8. 2010
  3. ncbi Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 32:296-300. 2002
  4. ncbi Developing therapies for advanced bladder cancer
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Expert Opin Investig Drugs 11:109-15. 2002
  5. ncbi Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer
    H Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Japan
    BJU Int 93:42-6. 2004
  6. ncbi Asian trends in prostate cancer hormone therapy
    Hideyuki Akaza
    Dept of Urology, University of Tsukuba, Ibaraki 305 8576, Japan
    Gan To Kagaku Ryoho 29:1951-61. 2002
  7. ncbi Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective
    Hideyuki Akaza
    Urology and Andrology, Functional and Regulatory Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, 305 8575, Japan
    Cancer Sci 97:243-7. 2006
  8. ncbi Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy
    Naoto Miyanaga
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba City, Ibaraki 305 8575, Japan
    Jpn J Clin Oncol 37:852-7. 2007
  9. ncbi Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba 305 8576, Japan
    Jpn J Clin Oncol 37:755-62. 2007
  10. ncbi Report from the 1st Japanese Urological Association-Japanese Society of Medical Oncology joint conference, 2006: 'A step towards better collaboration between urologists and medical oncologists'
    Hideyuki Akaza
    University of Tsukuba, Graduate School of Comprehensive Human Sciences, Tsukuba University Hospital, Japan
    Int J Urol 14:375-83. 2007

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. ncbi A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 2 1 1 Amakubo, Tsukuba 305 0005, Japan
    Int J Clin Oncol 11:434-40. 2006
    ..Efficacy and safety at this dose was evaluated (phase 2)...
  2. doi Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    Oncology 78:323-8. 2010
    ..The primary endpoint was prostate-specific antigen (PSA) response...
  3. ncbi Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 32:296-300. 2002
    ..However, to date there have been no case-controlled clinical studies carried out to compare the circulating concentrations of isoflavones in prostate cancer patients and control subjects...
  4. ncbi Developing therapies for advanced bladder cancer
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Expert Opin Investig Drugs 11:109-15. 2002
    ....
  5. ncbi Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer
    H Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Japan
    BJU Int 93:42-6. 2004
    ..Goserelin support therefore improves clinical DFS and reduces DRM after radiotherapy or radical prostatectomy. Adjuvant goserelin may offer greater clinical benefits than neoadjuvant hormonal treatment...
  6. ncbi Asian trends in prostate cancer hormone therapy
    Hideyuki Akaza
    Dept of Urology, University of Tsukuba, Ibaraki 305 8576, Japan
    Gan To Kagaku Ryoho 29:1951-61. 2002
    ..The main findings of the conference are reported in this review...
  7. ncbi Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective
    Hideyuki Akaza
    Urology and Andrology, Functional and Regulatory Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, 305 8575, Japan
    Cancer Sci 97:243-7. 2006
    ..The effectiveness of PADT in LAPC, in particular, is worthy of attention. There is a possibility that therapeutic strategies for LPC and LAPC may change dramatically in the near future...
  8. ncbi Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy
    Naoto Miyanaga
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba City, Ibaraki 305 8575, Japan
    Jpn J Clin Oncol 37:852-7. 2007
    ..The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data...
  9. ncbi Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba 305 8576, Japan
    Jpn J Clin Oncol 37:755-62. 2007
    ..This phase II study investigated efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma (RCC)...
  10. ncbi Report from the 1st Japanese Urological Association-Japanese Society of Medical Oncology joint conference, 2006: 'A step towards better collaboration between urologists and medical oncologists'
    Hideyuki Akaza
    University of Tsukuba, Graduate School of Comprehensive Human Sciences, Tsukuba University Hospital, Japan
    Int J Urol 14:375-83. 2007
    ..This report presents a roundup of the 1st Japanese Urological Association-Japanese Society of Medical Oncology Joint Conference...
  11. ncbi Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
    BJU Int 98:573-9. 2006
    ....
  12. ncbi A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up
    H Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    BJU Int 91:33-6. 2003
    ..To evaluate the effect of primary hormonal therapy for patients with localized and locally advanced prostate cancer...
  13. ncbi The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy
    Hideyuki Akaza
    Institute of Clinical Medicine, University of Tsukuba, Japan
    Asian Pac J Cancer Prev 8:3-12. 2007
    ..Prednisone and dexamethasone are used for secondary hormonal therapy. External beam radiotherapy, radioisotopic drugs such as strontium 89, and bisphosphonates are common choices to control bone pain...
  14. ncbi Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Jpn J Clin Oncol 37:201-6. 2007
    ..However, a second-line therapy is still required for patients with recurrent TCC who discontinued MVAC because of toxicity or have MVAC refractory tumors...
  15. ncbi Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Ibaraki, Japan
    BJU Int 99:10-2; discussion 17-8. 2007
    ....
  16. ncbi A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 33:382-90. 2003
    ..In Japan, however, only BCG Tokyo 172 strain is commercially available. We therefore designed a clinical study of PMCJ-9 (BCG Connaught strain) for obtaining approval from Japanese Ministry of Health, Labor and Welfare...
  17. ncbi The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tennodai 1 1 1, Tsukuba, Ibaraki 305 8578, Japan
    J Urol 176:S47-9. 2006
    ....
  18. ncbi Advanced prostate cancer treatment guidelines: a global perspective; trends of hormone therapy in Japan
    H Akaza
    Department of Urology, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    BJU Int 94:5. 2004
  19. doi Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis
    Hideyuki Akaza
    Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Ibaragi, Japan
    Jpn J Clin Oncol 40:684-9. 2010
    ..In this paper, the clinical response to our combination therapy is reported...
  20. ncbi Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group
    H Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 30:131-6. 2000
    ..In this situation, primary hormone therapy is an alternative treatment option. We have designed a prospective randomized study of the effects of primary hormone therapy for such patients...
  21. doi Current status and prospects of androgen depletion therapy for prostate cancer
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Best Pract Res Clin Endocrinol Metab 22:293-302. 2008
    ....
  22. ncbi Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 34:329-36. 2004
    ..Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline...
  23. ncbi Advances in chemotherapy of invasive bladder cancer
    H Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Curr Opin Urol 10:453-7. 2000
    ..Such individualization of therapy would aid in future establishment of bladder-preserving treatment methods for invasive bladder cancers...
  24. ncbi Higher consumption of green tea may enhance equol production
    Naoto Miyanaga
    Department of Urology, Post Graduate University of Tsukuba, Ibaraki, 305 8575, Japan
    Asian Pac J Cancer Prev 4:297-301. 2003
    ..In the present study, we examined relationships between type of food intake and the capacity for equol production in Japanese subjects...
  25. ncbi The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305 8576, Japan
    Gan To Kagaku Ryoho 31:1285-95. 2004
    ....
  26. ncbi Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Ja
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Jpn J Clin Oncol 34:20-8. 2004
    ..To evaluate bicalutamide (Casodex) 80 mg as a component of maximum androgen blockade (MAB) in Japanese patients with previously untreated advanced prostate cancer...
  27. doi Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Cancer 115:3437-45. 2009
    ..4 years indicated that CAB significantly (P<.001) prolonged the time to progression and the time to treatment failure. In the current report, survival data from a long-term follow-up (median, 5.2 years) were analyzed...
  28. ncbi Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group
    Y Homma
    Department of Urology, University of Tokyo, Japan
    Int J Urol 6:229-37; discussion 238-9. 1999
    ..The effects of preoperative androgen deprivation were explored in the patients who received radical prostatectomy and subsequent adjuvant endocrine therapy for prostate cancer...
  29. ncbi [Platinum compounds in cancer therapy--past, present, and future]
    H Akaza
    Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 28:625-35. 2001
    ..In preclinical studies, ZD0473 has been shown to by-pass some major mechanisms of resistance and has the potential to achieve these objectives and is now being evaluated in clinical studies in both Japan and the West...
  30. ncbi A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study
    N Miyanaga
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Int J Urol 7:41-8. 2000
    ..A prospective study was performed to investigate combined treatment with intra-arterial chemotherapy and radiation therapy for bladder preservation in locally invasive bladder cancer...
  31. ncbi [Chemotherapy and radiotherapy for urological cancer]
    Naoto Miyanaga
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 29:709-16. 2002
    ..Moreover, brachytherapy and proton and ion beam therapy are expected to prove useful in prostate cancer therapy...
  32. ncbi Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy
    Masaharu Hata
    Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Int J Radiat Oncol Biol Phys 64:1371-9. 2006
    ..To present outcomes of bladder-preserving therapy with proton beam irradiation in patients with invasive bladder cancer...
  33. doi Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling
    T Kojima
    Department of Urology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tennoudai, Tsukuba, Japan
    Oncogene 28:297-305. 2009
    ..These data suggest that CXXC4 plays a critical role in tumor progression of RCC through Wnt signaling. Wnt signaling could thus be a potential molecular target in RCC indicating decreased CXXC4 expression...
  34. doi Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association
    Eiji Kikuchi
    Working Group of the Bladder Cancer Registration Committee of the Japanese Urological Association, Department of Urology, Keio University School of Medicine, Tokyo, Japan
    Int J Urol 16:279-86. 2009
    ....
  35. ncbi Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients
    Takahiro Kojima
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 2 1 1 Amakubo, Tsukuba City, Ibaraki 305 8576, Japan
    Jpn J Clin Oncol 34:137-41. 2004
    ..The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC...
  36. doi A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety
    Hirotsugu Uemura
    Department of Urology, University of Tsukuba, Graduate School of Comprehensive Human Sciences, Tsukuba 305 8576, Japan
    Jpn J Clin Oncol 40:194-202. 2010
    ..This study aims to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (RCC)...
  37. ncbi Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP
    Shiro Hinotsu
    Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1 1 1 Tennodai, Tsukuba City, Ibaraki Prefecture, 305 8575, Japan
    Jpn J Clin Oncol 37:775-81. 2007
    ....
  38. ncbi Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results
    Yukio Homma
    Department of Urology, University of Tokyo, Tokyo, Japan
    Int J Urol 11:295-303. 2004
    ..The effects of preoperative androgen deprivation on the outcomes of prostate cancer patients who received radical prostatectomy and subsequent adjuvant endocrine therapy have not yet been fully evaluated...
  39. ncbi The limited efficacy of methotrexate, actinomycin D and cisplatin (MAP) for patients with advanced testicular cancer
    Jun Miyazaki
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 33:391-5. 2003
    ..Combination chemotherapy of methotrexate, actinomycin D and cisplatin (MAP) is reported to be effective against gestational choriocarcinoma...
  40. pmc Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers
    M Tanaka
    Department of Urology, Nara Medical University, Kashihara, Japan
    Prostate Cancer Prostatic Dis 12:247-52. 2009
    ..These results suggest the possibility of converting equol non-producers to producers by prolonged and consistent soy isoflavones consumption...
  41. ncbi [Neoadjuvant chemotherapy in muscle-invasive bladder cancer]
    Naoto Miyanaga
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Gan To Kagaku Ryoho 34:1745-9. 2007
    ..Bladder preservation in selected patients on the basis of response to neoadjuvant chemotherapy is a feasible approach. The goal now must be to find more effective drugs and to better predict the individual response to therapy...
  42. doi An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    Seiji Naito
    Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Cancer Chemother Pharmacol 66:1065-70. 2010
    ..4:1. The aim of this trial was to investigate the efficacy and safety of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma (RCC)...
  43. ncbi [Usefulness and positioning of MAB therapy for prostate cancer]
    Hideyuki Akaza
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 32:1507-20. 2005
    ....
  44. ncbi Case of alpha-fetoprotein-producing transitional cell carcinoma of the renal pelvis
    Yoshiyuki Shiga
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Int J Urol 11:117-8. 2004
    ..To our knowledge, this has not been reported previously. We present the first case of an alpha-fetoprotein-producing transitional cell carcinoma of the renal pelvis in a 70-year-old female...
  45. ncbi [The possibility of S-1 for the treatment of patients with urological cancers]
    Hideyuki Akaza
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba, Japan
    Gan To Kagaku Ryoho 33:236-8. 2006
    ..Two phase II trials are being conducted to evaluate the efficacy and safety of S-1 as a single agent therapy for patients with hormone-refractory prostate cancer (HRPC) and renal cell carcinoma (RCC)...
  46. ncbi High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer
    J Miyazaki
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Int J Urol 7:258-62. 2000
    ..The present study was performed in order to investigate the efficacy and safety of high-dose chemotherapy for the treatment of patients with advanced testicular cancer...
  47. ncbi Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Can J Urol 12:77-80. 2005
    ..Having said that, fundamental research and clinical trials in recent years do indicate that the benefit of MAB is not merely an illusion...
  48. doi FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma
    Takahiro Kojima
    Department of Urology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
    Genes Chromosomes Cancer 49:379-89. 2010
    ..We conclude that FOXO1 and TCF7L2 are involved in metastasis and that molecules in these signaling pathways may be targets for diagnostic procedures and therapies for CRCC...
  49. ncbi Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer
    Yukio Homma
    Department of Urology, University of Tokyo, Tokyo, Japan
    Int J Urol 11:218-24. 2004
    ..We retrospectively compared the 5-year survival rates of T1b-T3N0M0 prostate cancer patients treated either by endocrine therapy plus radical prostatectomy or endocrine therapy alone...
  50. doi Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan
    S Naito
    Department of Urology, Faculty of Medicine, Kyushu University 71, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8585, Japan
    Jpn J Clin Oncol 38:365-72. 2008
    ..This study was undertaken to assess the feasibility of docetaxel in combination with prednisolone in Japanese patients with HRPC...
  51. ncbi AgNOR count in resting cells (resting NOR) is a new prognostic marker in invasive bladder tumor
    M Tomobe
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Anal Cell Pathol 22:193-9. 2001
    ..05). CONCLUSIONS: Resting NOR had a predictive value in the prognosis of patients with invasive bladder tumor...
  52. ncbi Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines
    K Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Mol Urol 4:43-6. 2000
    ..No dose-limiting side effects have been observed, and a few patients have had transient objective tumor regressions. Further trials with more frequent and, probably, longer immunization schedules are needed to define efficacy...
  53. ncbi [Management of a hormone dependent cancer with endocrine therapy--prostate cancer]
    S Tsukamoto
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan
    Gan To Kagaku Ryoho 28:917-26. 2001
    ..However, to date there is still no effective therapy for patients who have hormone refractory disease...
  54. ncbi Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer
    T Oikawa
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
    BJU Int 92:1009-15. 2003
    ....
  55. ncbi [Significance of current bio- and molecular-markers in urological cancers]
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba, Ibaraki 305 8575, Japan
    Gan To Kagaku Ryoho 31:1008-14. 2004
    ..In renal cell carcinoma (RCC), unfortunately, no definitive biomarker is available for its diagnosis and monitoring. Thus, we must find new specific bio- and molecular-markers that reflect the biological activity of RCC...
  56. ncbi [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer]
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba
    Hinyokika Kiyo 49:771-7. 2003
    ....
  57. ncbi Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents
    Hideyuki Akaza
    Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 34:86-9. 2004
    ....
  58. ncbi Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study
    Shiro Hinotsu
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Urology 67:545-9. 2006
    ..To ascertain the sustained prophylactic effect of intravesical bacille Calmette-Guérin (BCG) after transurethral resection of bladder tumor (TURBT), we compared the estimation of the duration of the effect with that of doxorubicin...
  59. doi Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan
    Ichiro Shintaku
    Department of Urology, Tohoku University Graduate School of Medicine, 1 1 Seiryo machi, Aoba ku, Sendai, Miyagi 980 8574, Japan
    Jpn J Clin Oncol 38:281-7. 2008
    ..Since the IGCC classification was based on patients treated between 1975 and 1990, we aimed to investigate whether survival has improved for more recently treated Japanese patients...
  60. ncbi Crescentic glomerulonephritis associated with renal cell carcinoma after cancer immunotherapy
    H Kai
    Department of Nephrology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba Japan
    J Nephrol 18:436-41. 2005
    ..Consequently, plasmapheresis is considered to be one of the effective and safe methods for patients with this association. We also discuss previous reports of RPGN associated with renal cell carcinoma, or RPGN after cancer immunotherapy...
  61. ncbi Treated natural history of superficial bladder cancer
    S Ozono
    Department of Urology, Nara Medical University, 840 Shijo Cho, Kashihara, Nara 634 8522, Japan
    Jpn J Clin Oncol 31:536-40. 2001
    ..The present study was conducted to examine the natural history of superficial bladder cancer...
  62. ncbi [Verify the optimum administration of anticancer agent--cisplatin]
    N Miyanaga
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
    Gan To Kagaku Ryoho 28:1339-44. 2001
    ..These protocols are used in many institutes, but the efficacy is not yet proven by comparison trials. In future, randomized prospective studies should be performed to test the usefulness of the regimens...
  63. ncbi Expression of ras p21 oncogene product on human bladder tumors
    N Moriyama
    Department of Urology, Branch Hospital, Japan
    Urol Int 44:260-3. 1989
    ....
  64. ncbi [Globalization of anti-cancer therapies]
    Hideyuki Akaza
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 29:205-14. 2002
    ..There have been some recent improvements and further progress is expected so that Japanese doctors can play a full role in the evaluation of new therapies...
  65. ncbi Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells
    Yoshihiro Ami
    Department of Biochemistry and Molecular Oncology, Comprehensive Human Science, Graduate School, University of Tsukuba, Ibaraki 305 8573, Japan
    Oncol Rep 13:75-80. 2005
    ..The unique profiling pattern of gene expression clearly correlated with cell morphology and metastatic potential. Such profiling might contribute to identifying the genes involved in the clinical characteristics of RCC...
  66. ncbi Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies
    Tarek Swellam
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennodai, Tsukuba, Ibaraki 305 8575, Japan
    Int J Urol 10:213-9. 2003
    ..In the in vivo study, cancer cells were implanted subcutaneously in the abdomens of mice, and the effects were assessed by the tumor growth...
  67. ncbi Does tumor size or microvascular invasion affect prognosis in patients with renal cell carcinoma?
    Tomoaki Miyagawa
    Department of Urology, Kitaibaraki Municipal General Hospital, Kitaibaraki, Ibaraki, Japan
    Jpn J Clin Oncol 37:197-200. 2007
    ..We retrospectively evaluated the effects of tumor size and microvascular tumor invasion on the clinical outcomes of patients who had undergone radical nephrectomy for renal cell carcinoma (RCC)...
  68. ncbi Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor
    Tsuneharu Miki
    Department of Urology, Kyoto Prefectural University of Medicine, Graduate School of Medical Sciences, Kyoto, Japan
    Int J Urol 14:54-9. 2007
    ..High-dose carboplatin, etoposide, ifosfamide chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) was investigated as first-line chemotherapy in patients with advanced testicular GCT...
  69. ncbi Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers
    Tomonori Habuchi
    Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Cancer 98:1635-42. 2003
    ....
  70. ncbi The 2nd conference on Asian trends in prostate cancer hormone therapy
    Hideyuki Akaza
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305 8576, Japan
    Gan To Kagaku Ryoho 30:1533-42. 2003
    ..quot; This session included 2 lively discussions, on whether Asian physicians can apply Western clinical data to Asian patients, and the need for Asian clinical data and developing clinical trials in the region, respectively...
  71. ncbi Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis
    Toshiaki Kinouchi
    Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka, 537 8511, Japan
    J Cancer Res Clin Oncol 132:499-504. 2006
    ....
  72. ncbi Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model
    Atsushi Yamauchi
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    J Urol 175:348-52. 2006
    ..In the current study we determined whether antiandrogen would promote or suppress the prostate carcinogenesis when administration was begun at a later period of carcinogenesis...
  73. ncbi Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology
    Kogenta Nakamura
    Department of Urology, Aichi Medical University School of Medicine, Aichi 480 1195, Japan
    Int J Oncol 28:965-70. 2006
    ..Furthermore, the discovery of a susceptibility and or a inhibitory factor may eventually lead to the development of a novel drug targeting the respective factor for the improvement of anticancer chemotherapy...
  74. ncbi Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer
    Ei Ichiro Takaoka
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 36:60-3. 2006
    ..The mortality rate is as high as 21-48% according to a recent review. The present case indicates that the neutropenic colitis can occur under neutropenic conditions induced by the standard-dose chemotherapy for solid cancer...
  75. ncbi Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system
    K Uchida
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 30:95-100. 2000
    ..As a primary screening for prostate cancer, measurement of serum prostate-specific antigen(PSA) added to the health checkup system has not been assessed...
  76. ncbi [Comparison of management of advanced cancer in various organs]
    H Akaza
    Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 28:1845-55. 2001
    ..In summary, the treatment of advanced disease provides a test bed for new agents, but this need to develop better cancer therapies must be balanced against patient needs for a pain-free and comfortable end to life...
  77. doi Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men
    K Fujimoto
    Department of Urology, Nara Medical University, Kashihara, Japan
    Prostate Cancer Prostatic Dis 11:252-7. 2008
    ..Elucidating the mechanism of equol production may be promising in developing strategies for chemoprevention against prostate cancer...
  78. doi Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin
    Akira Joraku
    Graduate School of Comprehensive Human Sciences, Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan
    BJU Int 103:686-93. 2009
    ....
  79. ncbi Type 1, P and S fimbriae, and afimbrial adhesin I are not essential for uropathogenic Escherichia coli to adhere to and invade bladder epithelial cells
    Jun Miyazaki
    Department of Infection Biology, Institute of Basic Medical Sciences, University of Tsukuba, 1 1 1 Tennodai, Tsukuba shi, Ibaraki 305 8575, Japan
    FEMS Immunol Med Microbiol 33:23-6. 2002
    ..In conclusion, this study demonstrates that type 1 fimbriae, P fimbriae, S fimbriae, and afimbrial adhesin I are not required for UPEC to adhere to and invade uroepithelial cells...
  80. ncbi [Urological cancer]
    Naoto Miyanaga
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Gan To Kagaku Ryoho 36:193-8. 2009
    ..Thus, new anticancer drugs such as taxanes and gemcitabine were added to cisplatin-based chemotherapy, and a treatment of urological cancer is progressing...
  81. ncbi Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity
    Koji Kawai
    University of Tsukuba, Institute of Clinical Medicine, Department of Urology, Tsukuba, Ibaraki, Japan
    Int J Urol 12:284-9. 2005
    ..In the present study, we used the subfraction profile of LCA-binding AFP to diagnose and monitor testicular tumor activity...
  82. ncbi Telomerase is upregulated in irreversible preneoplastic lesions during bladder carcinogenesis in rats
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305 8575
    Jpn J Cancer Res 93:495-500. 2002
    ....
  83. ncbi Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
    Jpn J Clin Oncol 37:603-8. 2007
    ..Here, we compare it with the regimen of docetaxel once every 3 weeks (q3w) plus daily prednisone (PSL) based on a TAX 327 trial in order to clarify the efficacy and toxicity of docetaxel regimens in Japan...
  84. ncbi [Sorafenib(Nexavar)]
    Naoto Miyanaga
    Dept of Urology, Institute of Clinical Medicine, Post Graduate University of Tsukuba, Japan
    Gan To Kagaku Ryoho 36:1029-33. 2009
    ..For the future, research of biomarker, adverse drug reaction, and combined regimens are needed to maximize the effects of molecular-targeted drugs...
  85. ncbi Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer
    Koji Kawai
    Institute of Clinical Medicine, Department of Urology, University of Tsukuba, 1 1 1 Tennodai, Tsukuba City, Ibaraki 305, Japan
    Jpn J Clin Oncol 33:127-31. 2003
    ..The purpose of this study was to assess the feasibility of a TIP regimen for Japanese patients with advanced germ cell cancer...
  86. ncbi Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma
    T Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Eur Urol 38:331-8. 2000
    ..Similarly, during carcinogenesis, cell-cell adhesion might alter leading to a more aggressive phenotype. Here we describe cadherin expression patterns in developing, adult, and neoplastic kidney...
  87. ncbi [A case of transitional cell carcinoma of the urinary bladder with high serum level of CEA and CA19-9]
    H Inai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba
    Hinyokika Kiyo 47:583-6. 2001
    ..These serum markers have been reported to be elevated in 10 to 60% of patients with bladder tumor and are useful markers for evaluation of the treatment as suggested in the present case...
  88. ncbi [Prostate cancer]
    K Uchida
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki 305-8575, Japan
    Gan To Kagaku Ryoho 28:1469-74. 2001
    ....
  89. ncbi Hamartoma of the urinary bladder
    T Ota
    Department of Urology, Tokyo Metropolitan Komagome General Hospital, Japan
    Int J Urol 6:211-4. 1999
    ..Hamartomas of the urinary bladder are extremely rare. We report on a case in a 58-year-old female who presented with the chief complaint of pain on urination...
  90. ncbi Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation
    M Otsuka
    Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Nephron 88:144-8. 2001
    ..In terms of the severity of acute rejection or the onset of chronic rejection, DST induced a small benefit, however, which seemed to disappear within 8 years after transplantation...
  91. pmc Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes
    K Kawai
    Department of Urology, University of Tsukuba, Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan
    Clin Exp Immunol 134:264-9. 2003
    ..At autopsy, viable RCC cells were found in multiple metastatic sites. However, only diffuse fibrous tissue was observed in the responding RPLN mass. Apparent histological divergence was observed between primary and metastatic sites...
  92. ncbi [Recent advancement in diagnosis and treatment of prostate cancer--general concepts]
    Hideyuki Akaza
    Department of Urology, Graduate University of Tsukuba
    Nihon Rinsho 63:237-40. 2005
    ..In addition, useful strategy for the timing of radical therapy for localized prostate cancer is warranted to be established. These strategies are essential to avoid over-diagnosis and over-treatment...
  93. ncbi [Reevaluation of MAB therapy and progress of endocrine therapy]
    Laurence Klotz
    Gan To Kagaku Ryoho 32:705-28. 2005
  94. ncbi Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report
    Naoto Miyanaga
    Department of Urology, Graduate School of Comprehensive Human Sciences, Tsukuba, Japan
    Int J Urol 13:1514-8. 2006
    ..It is expected to become a new diagnostic modality for prostate cancer. The aim of this study was to examine the usefulness of elastography in the diagnosis of prostate cancer...
  95. ncbi A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome
    Koji Kawai
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba Graduate School of Comprehensive Human Sciences, Tsukuba City, Ibaraki, Japan
    Jpn J Clin Oncol 36:665-7. 2006
    ..The urological oncologist should be aware of the potential complications TLS and choriocarcinoma syndrome in cases of rapidly progressive and high-volume choriocarcinoma...
  96. ncbi [Cancer chemotherapy in the future. Discussion]
    Hideyuki Akaza
    Gan To Kagaku Ryoho 30:1422-33. 2003
  97. ncbi Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective
    Atsushi Mizokami
    Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Japan
    BJU Int 99:6-9; discussion 17-8. 2007
    ....
  98. ncbi Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305 8575, Japan
    Int J Oncol 23:1049-54. 2003
    ..Detection of cadherin-6 mRNA in non-metastatic presurgical RCC patients suggests that careful follow-up study is necessary in these patients...
  99. ncbi The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma
    Toru Shimazui
    Department of Urology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba City, Ibaraki, Japan
    Cancer 101:963-8. 2004
    ....
  100. ncbi Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study
    Satoru Ueno
    Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Int J Urol 13:1494-500. 2006
    ..A retrospective review of patients with localized and locally advanced prostate cancer was performed to evaluate the efficacy of primary hormonal therapy and predict long-term prognosis in these patients...
  101. doi Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition)
    Sadao Kamidono
    Int J Urol 15:1-18. 2008